ROX Medical is a technology company.
ROX Medical has raised $89.0M across 4 funding rounds.
ROX Medical has raised $89.0M in total across 4 funding rounds.
ROX Medical has raised $89.0M in total across 4 funding rounds.
ROX Medical's investors include Andera Partners, Domain Associates, Forbion, T1D Fund.
ROX Medical is a privately held medical device company developing the ROX Coupler, an innovative interventional vascular therapy for patients with uncontrolled hypertension. The device enables a minimally invasive, reversible procedure performed in under one hour in a standard catheterization lab, without sedation, targeting the over 16 million Americans on medication yet failing to control blood pressure[2][3]. It serves patients with resistant hypertension (e.g., stage 2 >160 mmHg), physicians in vascular labs, and healthcare systems addressing a major cardiovascular challenge affecting 67 million U.S. adults, with proven 12-month outcomes showing mean drops of 27 mmHg (office) and 13 mmHg (ambulatory) in the ROX CONTROL HTN study published in *The Lancet*[2]. Growth momentum includes commercial availability in Europe under CE mark and ongoing U.S. studies, positioning it as a potential major advance per experts like Dr. Melvin Lobo[2].
ROX Medical emerged as a pioneer in hypertension therapy, based in San Clemente, California, with a focus on interventional solutions for uncontrolled cases where drugs fail[2][3]. Key leadership includes CEO Rodney Brenneman, who highlighted the unmet need for five million U.S. stage 2 hypertension patients in 2017 announcements[2]. The company's pivotal moment came with the 2017 publication of 12-month ROX CONTROL HTN study results in *The Lancet*, validating durable blood pressure reductions and sparking recognition as a "major advance"[2]. Early traction built on this evidence, leading to European commercialization and further trials, humanizing its mission through clinician endorsements and patient impact data[2][3].
(Note: Distinct from RoX Health, a German healthcare innovation studio[1].)
ROX Medical rides the wave of interventional cardiology advancements for cardiovascular diseases, a top global killer, where digital and device innovations target heart failure, obesity, and hypertension amid rising prevalence[1][2]. Timing aligns with limitations of oral therapies—failing 16 million medicated U.S. patients—fueling demand for minimally invasive options like renal denervation alternatives[2]. Market forces favor it: aging populations, CDC-highlighted epidemics, and post-*Lancet* validation drive clinician adoption and payer interest[2]. It influences the ecosystem by expanding outpatient hypertension management, potentially reducing hospitalizations and inspiring hybrid device-drug therapies in medtech.
ROX Medical's path forward hinges on U.S. FDA approval, leveraging CONTROL HTN data and additional trials to capture resistant hypertension market share[2]. Trends like personalized vascular interventions and AI-enhanced diagnostics will amplify its impact, especially as obesity-hypertension links grow[1][2]. Influence may evolve from niche therapy to standard-of-care, transforming uncontrolled hypertension outcomes and echoing its *Lancet*-proven promise as a "major advance" for millions[2].
ROX Medical has raised $89.0M across 4 funding rounds. Most recently, it raised $40.0M Series E in September 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2016 | $40.0M Series E | Andera Partners, Domain Associates, Forbion, T1D Fund | |
| Sep 1, 2012 | $6.0M Series D | Domain Associates, T1D Fund | |
| Jun 1, 2008 | $33.0M Series C | Domain Associates, T1D Fund | |
| Jul 1, 2006 | $10.0M Series B | Domain Associates, T1D Fund |